Monteverde Associates Investigates Recent Mergers Affecting Shareholders of Four Companies

Introduction to Monteverde & Associates

Monteverde & Associates PC, a top-tier class action law firm based in the Empire State Building, has a notable reputation for recovering significant financial returns for shareholders through active litigation and investigations. Recognized as a Top 50 firm in the ISS Securities Class Action Services Report for 2024, they specialize in navigating the intricate landscape of securities law and shareholder rights.

Investigation Overview

On May 2, 2025, Monteverde & Associates announced that it is currently conducting investigations concerning several proposed mergers involving well-known companies: Avalon GloboCare Corp. (NASDAQ: ALBT), Endo, Inc. (OTC: NDOI), Dun & Bradstreet Holdings, Inc. (NYSE: DNB), and ReShape Lifesciences Inc. (NASDAQ: RSLS). Shareholders of these companies may want to understand how these mergers will affect their financial interests, particularly with specific equity stakes tied to the mergers.

Avalon GloboCare Corp. (ALBT)

Avalon GloboCare is under scrutiny due to its proposed merger with YOOV Group Holding Limited. According to the merger agreement, Avalon equity holders are expected to receive an equity stake of about 2.5% to 2.2% in the new company, which raises questions regarding the fairness of the deal to existing shareholders. Such a significant merger could reshape the company's market share and future profitability, making it crucial for shareholders to be informed of their rights and potential financial impacts.

More information here.

Endo, Inc. (NDOI)

Endo, a pharmaceutical company, is merging with Mallinckrodt plc, which entitles Endo shareholders to an approximate 49.9% stake in the joint enterprise. This substantial ownership percentage can greatly influence shareholders' dividends and decision-making processes within the merged entity. Understanding these details can provide shareholders insights into their investment’s future trajectory.

Learn more about the investigation.

Dun & Bradstreet Holdings, Inc. (DNB)

The proposed merger between Dun & Bradstreet and Clearlake Capital Group promises each Dun & Bradstreet shareholder a cash value of $9.15 per share. Such exchanges require rigorous evaluation to ensure that they reflect the fair market value of shares. Shareholders should be aware of their rights and the potential for litigation if unfair practices are suspected.

Explore details here.

ReShape Lifesciences Inc. (RSLS)

Lastly, ReShape Lifesciences announced a significant merger with Vyome Therapeutics, structured as an all-stock transaction where ReShape shareholders will own approximately 11.1% of the new consolidated company. The implications of stock dilution and restructuring must be meticulously assessed by shareholders as they consider their future stake in the company.

Visit for more info.

Conclusion

Montverde & Associates stresses that not all law firms operate similarly. Potential clients are encouraged to ask critical questions about class actions filed, past recovery successes, and overall firm performance before deciding to engage legal representation. Understanding the dynamics of each merger and the rights of shareholders is essential as they navigate these changes.

For anyone invested in the aforementioned companies or concerned about the mergers’ impact on their holdings, Monteverde & Associates offers free consultations and additional insights into their rights as investors. Interested parties can reach Juan Monteverde, Esq. at [email protected] or via phone at (212) 971-1341.